Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.

doi:10.3389/fimmu.2021.751407

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Frontiers in immunology - 1 Jan 2021

Li Yan, Ma Yiqi, Wu Zijun, Zeng Fanxin, Song Bin, Zhang Yanrong, Li Jinxing, Lui Su, Wu Min

Abstract excerpt

Objectives: For colorectal cancer patients, traditional biomarker deficient mismatch repair/microsatellite instability (dMMR/MSI) is an accurate predictor of immune checkpoint inhibitors (ICIs). Recent years, researchers considered tumor mutation burden (TMB) as another predictive biomarker which means the number of nonsynonymous mutations in cancer cells. Several studies have proven that TMB can evaluate the...

Topics

Biomarkers, Tumor
Cohort Studies
Colorectal Neoplasms
Humans
Immune Checkpoint Inhibitors
Mutation
Randomized Controlled Trials as Topic
Treatment Outcome

Source

Open in PubMed

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Open full text

Identifiers

PMID: 34659255
DOI: 10.3389/fimmu.2021.751407
PMCID: PMC8511407

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.